Published in Eur J Gastroenterol Hepatol on November 01, 1995
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut (2008) 1.75
What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut (1998) 1.43
Interstitial nephritis from mesalazine: case report and literature review. Pediatr Nephrol (2004) 1.13
Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci (2002) 0.98
Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol (2009) 0.89
Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Br J Clin Pharmacol (2000) 0.84
Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. United European Gastroenterol J (2015) 0.83
Second Korean guidelines for the management of ulcerative colitis. Intest Res (2017) 0.83
Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis. Med Sci Monit (2014) 0.82
Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterol Res Pract (2015) 0.79
Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease. Mediators Inflamm (1998) 0.79
Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial. Patient Prefer Adherence (2008) 0.76
5-aminosalicylates in inflammatory bowel disease--the more the merrier? Eur J Gastroenterol Hepatol (1995) 0.75
Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet (1990) 9.49
Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology (1988) 8.27
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut (1999) 7.14
The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med (1995) 6.73
Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst (1995) 6.07
Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol (1998) 5.77
Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet (1999) 5.27
Identification of Campylobacter pyloridis isolates by restriction endonuclease DNA analysis. J Clin Microbiol (1986) 5.15
The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology (1996) 4.69
Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet (1993) 4.55
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 4.39
Long-term sequelae of Helicobacter pylori gastritis. Lancet (1995) 4.26
Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology (1989) 4.23
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med (1996) 4.11
Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med (1994) 4.00
Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice. Am J Gastroenterol (1999) 3.84
Functional gastroduodenal disorders. Gut (1999) 3.74
Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol (1994) 3.22
Randomised trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bileduct stones. Lancet (1997) 3.12
Needle-knife sphincterotomy as a precut procedure: a retrospective evaluation of efficacy and complications. Endoscopy (1996) 3.12
[Diversity of complaints in manifesting carcinoma of the gallbladder]. Ned Tijdschr Geneeskd (2007) 3.10
Sonic hedgehog regulates gastric gland morphogenesis in man and mouse. Gastroenterology (2001) 2.85
Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma. Lancet (1998) 2.84
Recurrent massive haematemesis from Dieulafoy vascular malformations--a review of 101 cases. Gut (1986) 2.74
Regular review: treatment of Helicobacter pylori infection. BMJ (2000) 2.73
Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol (1996) 2.73
The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis (1996) 2.66
An index of inflammatory activity in patients with Crohn's disease. Gut (1980) 2.62
Clostridial toxin in faeces of healthy infants. Lancet (1978) 2.58
Long-term follow-up after endoscopic sphincterotomy for bile duct stones in patients younger than 60 years of age. Gastrointest Endosc (1996) 2.54
Double-balloon enteroscopy: indications, diagnostic yield, and complications in a series of 275 patients with suspected small-bowel disease. Endoscopy (2006) 2.43
Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut (1998) 2.38
The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology (1999) 2.37
Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol (1999) 2.33
Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter (1996) 2.26
Collagenous sprue--an unrecognized type of malabsorption. N Engl J Med (1970) 2.21
Equally high prevalences of infection with cagA-positive Helicobacter pylori in Chinese patients with peptic ulcer disease and those with chronic gastritis-associated dyspepsia. J Clin Microbiol (1997) 2.18
Heterogeneous Helicobacter pylori isolates from members of a family with a history of peptic ulcer disease. Gastroenterology (1996) 2.17
Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol (1997) 2.17
A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther (1999) 2.14
Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol (1995) 2.12
Treatment of bile duct lesions after laparoscopic cholecystectomy. Gut (1996) 2.12
Argon plasma coagulation in flexible gastrointestinal endoscopy: pilot experiences. Endoscopy (1997) 2.10
Prevalence of vacuolating cytotoxin production and distribution of distinct vacA alleles in Helicobacter pylori from China. J Infect Dis (1998) 2.09
Oral cimetidine in reflux esophagitis: a double blind controlled trial. Gastroenterology (1978) 2.07
[Changed diagnosis and treatment of hepatocellular carcinoma]. Ned Tijdschr Geneeskd (1996) 2.04
Intestinal metaplasia and Helicobacter pylori: an endoscopic bioptic study of the gastric antrum. Gut (1992) 1.96
HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut (1999) 1.94
14C-urea breath test in C pylori gastritis. Gut (1989) 1.89
Seroconversion for Helicobacter pylori. Lancet (1993) 1.88
Time trends in gastric carcinoma: changing patterns of type and location. Am J Gastroenterol (1992) 1.88
Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol (1996) 1.86
cagA-positive Helicobacter pylori populations in China and The Netherlands are distinct. Infect Immun (1998) 1.84
Gastric non-Hodgkin lymphomas of mucosa-associated lymphoid tissue are not associated with more aggressive Helicobacter pylori strains as identified by CagA. Am J Clin Pathol (1996) 1.84
Endoscopic palliative treatment in pancreatic cancer. Gastrointest Endosc (1986) 1.84
Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet (1987) 1.83
Analysis of the lympho-plasmacytic infiltrate in Crohn's disease with special reference to identification of lymphocyte-subpopulations. Gut (1976) 1.83
Biliary endoprostheses in elderly patients with endoscopically irretrievable common bile duct stones: report on 117 patients. Gastrointest Endosc (1995) 1.82
Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol (1996) 1.80
Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease. Gut (1993) 1.79
A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology (1997) 1.79
A study of 280 cases of neonatal meningitis in The Netherlands. J Infect (1984) 1.79
Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Aliment Pharmacol Ther (1999) 1.76
Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology (1988) 1.75
Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease. Gastroenterology (1999) 1.74
Helicobacter pylori: a true carcinogen? Eur J Gastroenterol Hepatol (1998) 1.72
Endosonography and computed tomography of esophageal carcinoma. Preoperative classification compared to the new (1987) TNM system. Gastroenterology (1989) 1.70
Twenty-four-hour pH measurements in morbid obesity: effects of massive overweight, weight loss and gastric distension. Eur J Gastroenterol Hepatol (1996) 1.70
Acute upper gastrointestinal bleeding in the Amsterdam area: incidence, diagnosis, and clinical outcome. Am J Gastroenterol (1997) 1.69
Intragastric balloon in the treatment of super-morbid obesity. Double-blind, sham-controlled, crossover evaluation of 500-milliliter balloon. Gastroenterology (1990) 1.67
Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology (1997) 1.67
Impaired anamnestic cellular immune response in patients with Crohn's disease. Gut (1975) 1.65
A patient with osteomalacia as single presenting symptom of gluten-sensitive enteropathy. J Intern Med (1992) 1.64
Surveillance in Barrett's oesophagus: a critical reappraisal. Scand J Gastroenterol Suppl (2002) 1.63
Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol (2000) 1.62
Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol (1997) 1.62
Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther (1998) 1.61
Model bile and bile salts accelerate mucin secretion by cultured dog gallbladder epithelial cells. Gastroenterology (1995) 1.61
Intestinal endotoxemia. Clinical significance. Gastroenterology (1988) 1.59
Benign biliary strictures. Surgery or endoscopy? Ann Surg (1993) 1.59
Loss of E-cadherin expression in early gastric cancer. Histopathology (1999) 1.59
Intragastric balloons for morbid obesity: results, patient tolerance and balloon life span. Br J Surg (1990) 1.58
Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol (1999) 1.57
The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol (1998) 1.56